In vivo irradiations with patients undergoing radiation therapy: dana farber canc
接受放射治疗的患者的体内照射:达纳法伯癌症
基本信息
- 批准号:8013161
- 负责人:
- 金额:$ 28.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-15 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnimal ModelBiological AssayCalibrationClipDevelopmentDoseEvaluation MethodologyEventExposure toFeedbackGoalsHumanHuman ResourcesIndividualIonizing radiationMeasurementMeasuresMethodologyMethodsMyelosuppressionNail platePatientsPopulationProceduresProtocols documentationRadiationRadiation SyndromesRadiation therapyResearchRoleSamplingStagingTechniquesTechnologyTestingTooth structureTriageWhole-Body IrradiationWorkbasebiodosimetryclinically significantdesignhuman subjectin vivoinstrumentirradiationmeetingsmemberoperationprogramsprototyperesponsetechnique development
项目摘要
This core will have a critically important role in all 3 projects, providing access to a population of
pafients that provide a unique opportunity to develop the techniques and test the instrumentafion that is being developed. One of the potentially limiting factors in the development of accurate and effecfive
biodosimetry for triage of large populations potenfially exposed to clinically significant levels of ionizing radiafion has been the lack of suitable samples and subjects to test the validity ofthe assays and to facilitate the development of the techniques. Suitable samples/subjects require exposure to ionizing radiation in the dose range leading to the acute radiation syndrome, (2 -12 Gy). It would be completely unethical to expose human individuals to such doses of radiation for the purpose of developing the methodology and evaluation in animal models is not pracfical or relevant at this stage of development. We can instead, however, utilize pafients who receive such radiafion exposures as part of their treatment for myelosuppression and immunosupression. The DFCI is one ofthe few places in the world where there are large numbers of patients who as a part of their therapy, receive TBI in the dose ranges that are direcfiy pertinent to the levels needed to be measured in the event of a radiafion exposure event. In addition, there are ongoing research programs at DFCI that are invesfigafing the effects of such irradiations and strategies to minimize the effects of the exposures. This provides a unique opportunity to carry out the much-needed development and validafion of a methodology designed to make such measurements as a means of facilitating an effecfive response to an event in which large numbers of people potenfially are exposed to clinically significant dose of ionizing radiafion. The personnel from the DFCI will work with the personnel from the projects to make measurements in the TBI patient populafion in vivo in teeth and nails. Clippings of nails also will be obtained for use by project 2. When the prototype instruments suitable for deployed use by non-expert personnel are constructed, measurements will be made at DFCI using members ofthe team that have not previously been involved with the operafion ofthe instruments, providing a realisfic test ofthe capabilifies ofthe design, with important feedback for improvement of the prototypes.
这一核心将在所有3个项目中发挥至关重要的作用,为
为开发技术和测试正在开发的仪器提供了独特的机会。发展准确和有效的技术的潜在限制因素之一
对于潜在暴露于临床显著水平的电离辐射的大量人群的生物剂量学分类,一直缺乏合适的样本和受试者来测试分析的有效性,并促进技术的发展。合适的样本/受试者需要暴露在导致急性辐射综合征的剂量范围内的电离辐射(2-12GY)。为了制定方法而将人类个体暴露在这种剂量的辐射中是完全不道德的,在动物模型中进行评估在发展的这个阶段是不切实际或不相关的。然而,我们可以利用接受这种辐射暴露的患者作为他们治疗骨髓抑制和免疫抑制的一部分。DFCI是世界上为数不多的有大量患者在治疗过程中接受剂量范围内的TBI的地方之一,该剂量范围与发生辐射暴露事件时需要测量的水平直接相关。此外,DFCI正在进行研究计划,研究这种辐射的影响和将暴露影响降至最低的策略。这为开展急需的开发和验证方法提供了独特的机会,该方法旨在进行此类测量,作为促进对大量潜在暴露于临床显著剂量的电离辐射事件的有效反应的手段。DFCI的人员将与项目人员一起在活体内对脑外伤患者的牙齿和指甲进行测量。还将获得钉子的剪裁,以供项目2使用。当建造适合非专家人员部署使用的原型仪器时,将在DFCI使用以前没有参与过仪器操作的团队成员进行测量,为设计的能力提供现实的测试,并为原型的改进提供重要反馈。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EVA C GUINAN其他文献
EVA C GUINAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EVA C GUINAN', 18)}}的其他基金
26th Annual Fanconi Anemia Research Fund Scientific Symposium
第26届范可尼贫血研究基金年度科学研讨会
- 批准号:
8786035 - 财政年份:2014
- 资助金额:
$ 28.05万 - 项目类别:
Ex Vivo Alloanergization to Improve Immunity After Haploidentical Transplant
离体同种异能提高单倍体移植后的免疫力
- 批准号:
7772239 - 财政年份:2009
- 资助金额:
$ 28.05万 - 项目类别:
Ex Vivo Alloanergization to Improve Immunity After Haploidentical Transplant
离体同种异能提高单倍体移植后的免疫力
- 批准号:
7656464 - 财政年份:2009
- 资助金额:
$ 28.05万 - 项目类别:
rBPI21 & Endotoxin-directed Innate Immunity in Stem Cell Transplantation
重组BPI21
- 批准号:
7465106 - 财政年份:2008
- 资助金额:
$ 28.05万 - 项目类别:
rBPI21 & Endotoxin-directed Innate Immunity in Stem Cell Transplantation
重组BPI21
- 批准号:
7597147 - 财政年份:2008
- 资助金额:
$ 28.05万 - 项目类别:
CELLULAR CORRECTION OF CONGENITAL HEMATOPOIETIC DISORDERS
先天性造血障碍的细胞纠正
- 批准号:
6660971 - 财政年份:2002
- 资助金额:
$ 28.05万 - 项目类别:
CELLULAR CORRECTION OF CONGENITAL HEMATOPOIETIC DISORDERS
先天性造血障碍的细胞纠正
- 批准号:
6500777 - 财政年份:2001
- 资助金额:
$ 28.05万 - 项目类别:
PHASE I/II STUDY OF PIXY 321 FOR PATIENTS WITH MARROW FAILURE SYNDROMES
PIXY 321 针对骨髓衰竭综合征患者的 I/II 期研究
- 批准号:
6251881 - 财政年份:1997
- 资助金额:
$ 28.05万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 28.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




